- Home
- NRSN vs MDCX Comparison
NRSN vs MDCX Comparison
Compare NRSN & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRSN | MDCX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 15.9M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NRSN | MDCX |
|---|---|---|
| Price | $0.51 | $0.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.50 | ★ $14.50 |
| AVG Volume (30 Days) | 238.8K | ★ 2.8M |
| Earning Date | 03-31-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $583.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.15 |
| 52 Week High | $1.30 | $3.05 |
Technical Indicators
Market Signals| Indicator | NRSN | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 27.42 |
| Support Level | $0.39 | N/A |
| Resistance Level | $0.74 | $0.36 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 67.23 | 13.86 |
Price Performance
Historical ComparisonAbout NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.